English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/213764
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma

AuthorsGarcía-Carbonero, Rocío CSIC ORCID; Márquez‐Rodas, Iván; Cruz Merino, L. de la; Martínez-Trufero, Javier; Cabrera, Miguel Ángel; Piulats, Josep Maria; Capdevila, Jaume; Grande, Enrique; Martín‐Algarra, Salvador; Berrocal, Alfonso
KeywordsMerkel
Epidemiology
Diagnosis
Treatment
Immunotherapy
Issue DateOct-2019
PublisherAlphaMed Press
CitationOncologist 24(10): 1375-1383 (2019)
AbstractMerkel cell carcinoma (MCC) is a rare, aggressive, primary cutaneous neuroendocrine tumor that typically presents as an indurated nodule on sun‐exposed areas of the head and neck in the white population. Major risk factors include immunosuppression, UV light exposure, and advanced age. Up to 80% of MCC are associated with Merkel cell polyomavirus. About 50% of patients present with localized disease, and surgical resection with or without adjuvant radiotherapy is generally indicated in this context. However, recurrence rates are high and overall prognosis rather poor, with mortality rates of 33%–46%. MCC is a chemosensitive disease, but responses in the advanced setting are seldom durable and not clearly associated with improved survival. Several recent trials with checkpoint inhibitors (pembrolizumab, avelumab, nivolumab) have shown very promising results with a favorable safety profile, in both chemonaïve and pretreated patients. In 2017, avelumab was approved by several regulatory agencies for the treatment of metastatic MCC, the first drug to be approved for this orphan disease. More recently, pembrolizumab has also been approved by the U.S. Food and Drug Administration in this setting. Immunotherapy has therefore become the new standard of care in advanced MCC. This article reviews current evidence and recommendations for the diagnosis and treatment of MCC and discusses recent therapeutic advances and their implications for care in patients with advanced disease. This consensus statement is the result of a collaboration between the Spanish Cooperative Group for Neuroendocrine Tumors, the Spanish Group of Treatment on Head and Neck Tumors, and the Spanish Melanoma Group.
Publisher version (URL)http://dx.doi.org/10.1634/theoncologist.2018-0718
URIhttp://hdl.handle.net/10261/213764
DOIhttp://dx.doi.org/10.1634/theoncologist.2018-0718
Identifiersdoi: 10.1634/theoncologist.2018-0718
issn: 1083-7159
e-issn: 1549-490X
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.